Anaesthesia management and use of sugammadex in a patient with ullrich’s disease

Creative Commons License

Erbabacan E. , Koksal G. M. , Seker T. B. , Ekici B., Ozcan R. , Altindas F.

Turk Anesteziyoloji ve Reanimasyon Dernegi Dergisi, cilt.43, sa.5, ss.356-359, 2015 (Diğer Kurumların Hakemli Dergileri) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43 Konu: 5
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5152/tjar.2015.22448
  • Dergi Adı: Turk Anesteziyoloji ve Reanimasyon Dernegi Dergisi
  • Sayfa Sayıları: ss.356-359


© 2015 by Turkish Anaesthesiology and Intensive Care SocietyHere, we report anaesthesia management and the successful use of total intravenous anaesthesia and sugammadex in a patient with Ullrich’s disease. Propofol and remifentanyl infusion was used for anaesthesia. After the end of the surgery, when the train-of-four value was 0%, 4 mg kg−1 sugammadex was administered, and the patient was successfully extubated after 36 s. No adverse effects or safety concerns were observed. In conclusion, we suggest that the use of propofol infusion to avoid the use of inhalation anaesthetics and the use of sugammadex for the reversal of the effects of rocuronium is safe in patients with Ullrich’s disease.